[Comment] The essential medicines list for inflammatory bowel disease: time to raise the standards of global care

Unequal global access to inflammatory bowel disease (IBD) therapies creates profound health inequities. The increasing prevalence of IBD in Western countries, driven by high incidence rates and low mortality, places substantial strain on health-care resources and necessitates the development of innovative care models.1 Meanwhile, newly industrialised regions across Asia, Africa, and Latin America are facing rapid increases in IBD incidence, often in settings where health-care infrastructure and resources are least equipped to handle this growing burden.